The antidepressant mirtazapine-induced cytosolic Ca 2+ elevation and cytotoxicity in human osteosarcoma cells

Chinese Journal of Physiology

Volumn 49, Issue 6, 2006, Pages 290-297

  Pan, Chin Chuan ^a,b,c   Cheng, He Hsiung ^c   Huang, Chun Jen ^d,e   Lu, Yih Chau ^a   Chen, I Shu ^a   Liu, Shiuh Inn ^a   Hsu, Shu Shong ^a   Chang, Hong Tai ^a   Huang, Jong Khing ^a   Chen, Jin Shyr ^a   Jan, Chung Ren ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TIAN SHENG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Fura 2; MG63 cells; Mirtazapine; Osteosarcoma cells; Thapsigargin

Indexed keywords

CALCIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FURA 2; MIANSERIN; MIRTAZAPINE; PHOSPHOLIPASE C; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BONE TUMOR; CALCIUM SIGNALING; CELL SURVIVAL; CYTOSOL; DRUG EFFECT; HUMAN; METABOLISM; OSTEOSARCOMA; TIME; TUMOR CELL LINE;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BONE NEOPLASMS; CALCIUM; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL SURVIVAL; CYTOSOL; FURA-2; HUMANS; MIANSERIN; OSTEOSARCOMA; PHOSPHOLIPASE C; TIME FACTORS;

EID: 34247120234     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Annunziato, L., Amoroso, S., Pannaccione, A., Cataldi, M., Pignataro, G., D'Alessio, A., Sirabella, R., Secondo, A., Sibaud, L. and Di Renzo, G.F. Apoptosis induced in neuronal cells by oxidative stress: role played by caspases and intracellular calcium ions. Toxicol. Lett. 139: 125-133, 2003.
2. Barry, E.L. Expression of mRNAs for the alpha 1 subunit of voltage-gated calcium channels in human osteoblast-like cell lines and in normal human osteoblasts. Cal. Tissue Inter. 66: 145-150, 2000.
3. Benkert, O., Muller, M. and Szegedi, A. An overview of the clinical efficacy of mirtazapine. Human Psychopharmacol. 1: S23-S26, 2002.
4. Biswas, P.N., Wilton, L.V. and Shakir, S.A. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J. Psychopharmacol. 17: 121-126, 2003.
5. Bootman, M.D., Berridge, M.J. and Lipp, P. Cooking with calcium: the recipes for composing global signals from elementary events. Cell 91: 367-373, 1997.
6. Grasmader, K., Verwohlt, P.L., Kuhn, K.U., Dragicevic, A., Von Widdern, O., Zobel, A., Hiemke, C., Rietschel, M., Maier, W., Jaehde, U. and Rao, M.L. Population pharmacokinetic analysis of mirtazapine. Eur. J. Clin. Pharmacol. 60: 473-480, 2004.
7. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440-3450, 1985.
8. Gu, Y., Preston, M.R., el Haj, A.J., Hamid, J., Zamponi, G.W., Howl, J. and Publicover, S.J. Osteoblasts derived from load-bearing bones of the rat express both L-and T-like voltage-operated calcium channels and mRNA for alpha 1C, alpha 1D and alpha 1G subunits. Pflug. Arch. Eur. J. Phy. 438: 553-560, 1999.
9. Haapasalo-Pesu, K.M., Vuola, T., Lahelma, L. and Marttunen, M. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J. Child Adoles. Psychopharmacol. 14: 175-184, 2004.
10. Hirschfeld, R.M. The use of mirtazapine in difficult-to-treat patient populations. Human Psychopharmacol. 17: S33-S36, 2002.
11. 2+ handling and proliferation in human osteosarcoma cells. Basic Clin. Pharmacol. Toxicol. 95: 124-130, 2004.
12. Hui, C.K., Yuen, M.F., Wong, W.M., Lam, S.K. and Lai C.L. Mirtazapine-induced hepatotoxicity. J. Clin. Gastroenterol. 35: 270-271, 2002.
13. Hutchison, L.C. Mirtazapine and bone marrow suppression: a case report. J. Am. Geriatrics Soc. 49: 1129-1130, 2001.
14. 2+ movement and proliferation in human osteosarcoma cells. Pharmacology 69: 190-196, 2003.
15. Kast, R.E. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 9: 469-470, 2001.
16. 2+ entry in MG63 human osteosarcoma cells. Biochem. Pharmacol. 61: 1537-1541, 2001.
17. 2+ movement and cytotoxicity in human MG63 osteosarcoma cells. Basic Clin. Pharmacol. Toxicol. 95: 59-65, 2004.
18. Masand, P.S. and Gupta, S. Long-term side effects of newergeneration antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. An. Clin. Psychiatry 14: 175-182, 2000.
19. Nutt, D.J. Tolerability and safety aspects of mirtazapine. Human Psychopharmacol. 17: S37-S41, 2002.
20. Pirraglia, P.A., Stafford, R.S. and Singer, D.E. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Primary Care 5: 153-157, 2003.
21. Putney, J.W. Jr. A model for receptor-regulated calcium entry. Cell Calcium 7: 1-12, 1986.
22. Puzantian, T. Mirtazapine, an antidepressant. Am. J. Health-Syst. Ph. 55: 44-49, 1998.
23. Rezzonico, R., Cayatte, C., Bourget-Ponzio, I., Romey, G., Belhacene, N., Loubat, A., Rocchi, S., Van Obberghen, E., Girault, J.A., Rossi, B. and Schmid-Antomarchi, H. Focal adhesion kinase pp125FAK interacts with the large conductance calcium-activated hSlo potassium channel in human osteoblasts: potential role in mechanotransduction. J. Bone Min. Res. 18: 1863-1871, 2003.
24. 2+ ATPase. Pro. Natl. Aca. Soc. USA. 87: 2466-2470, 1990.
25. Thompson, A.K., Mostafapour, S.P., Denlinger, L.C., Bleasdale, J.E. and Fisher, S.K. The aminosteroid U-73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-NSH neuroblastoma cells. A role for Gp in receptor compartmentation. J. Biol. Chem. 266: 23856-23862, 1991.
26. Timmer, C.J., Sitsen, J.M. and Delbressine, L.P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 38: 461-474, 2000.
27. 2+ mobilization in MG63 human osteosarcoma cells. Horm. Res. 55: 265-270, 2001.